KNSA
Kiniksa Pharmaceuticals International, plc
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+50/100
Last price
76.70
▲ 0.39 (0.51%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
77.20
Prev close
76.31
Day high
77.32
Day low
73.84
Volume
378.74K
Market cap
$6.01B
P/E (TTM)
77.09
52W range
35.20 – 82.94
Day trading desk
Gap from prior close
+1.17%
Prior close 76.31
VWAP
76.69
+0.01% from price
Relative volume
1.15×
Normal
Session range
5.92%
73.00 – 77.32
Position in range
86%
Near session high
ATR (14D)
2.43
3.17% of price
Prior day high
76.79
PDH
Prior day low
75.29
PDL
Bid / ask spread
—
Quote not published
Session volume
686.02K
Avg 598.46K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.80%
-0.2%
1M
-1.05%
-2.2%
3M
+19.04%
+14.5%
6M
+57.52%
+39.3%
YTD
+86.88%
+72.6%
1Y
+100.29%
+83.9%
3Y
+343.81%
+261.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KNSA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+1.01M
Net buying
Buy transactions
28
1.67M shares
Sell transactions
11
661.57K shares
Net transactions
+39
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
2.74M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 3, 26 | MEGNA MICHAEL R Officer |
SELL | 4.60K | $369.38K | Direct |
| Sep 1, 26 | MEGNA MICHAEL R Officer |
— | 11.50K | — | Direct |
| Sep 1, 26 | PATEL SANJIV K Chief Executive Officer |
— | 31.32K | — | Indirect |
| Sep 1, 26 | PAOLINI JOHN F Officer |
— | 8.33K | — | Direct |
| Sep 1, 26 | RAGOSA MARK Chief Financial Officer |
— | 9.10K | — | Direct |
| Sep 1, 26 | MOAT ROSS Chief Operating Officer |
— | 8.29K | — | Direct |
| Aug 19, 26 | QUART BARRY D Director |
STOCK | 2.60K | $0 | Direct |
| Jul 31, 26 | LEVY RICHARD S Director |
— | 403 | — | Direct |
| Jul 29, 26 | COLE GORDON BRADLEY Director |
SELL | 3.67K | $299.09K | Direct |
| Jul 29, 26 | COLE GORDON BRADLEY Director |
STOCK | 4.50K | $0 | Direct |
| Jul 15, 26 | MEGNA MICHAEL R Officer |
STOCK | 279 | $17.21K | Direct |
| Jun 1, 26 | PATEL SANJIV K Chief Executive Officer |
— | 900.00K | — | Indirect |
| May 29, 26 | QUART BARRY D Director |
— | 2.80K | — | Direct |
| May 29, 26 | COLE GORDON BRADLEY Director |
— | 2.80K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS L.P. |
Unknown | — | Stock Award(Grant) |
BAKER BROTHERS LIFE SCIENCES, L.P. |
Director | — | Stock Award(Grant) |
LEVY RICHARD S |
Director | 22.36K | Conversion of Exercise of derivative security |
MALLEY THOMAS ROBERT |
Director | 87.31K | Conversion of Exercise of derivative security |
MEGNA MICHAEL R |
Officer | 29.06K | Sale |
MOAT ROSS |
Chief Operating Officer | 16.31K | Conversion of Exercise of derivative security |
PAOLINI JOHN F |
Officer | 69.92K | Conversion of Exercise of derivative security |
PATEL SANJIV K |
Chief Executive Officer | — | Conversion of Exercise of derivative security |
RAGOSA MARK |
Chief Financial Officer | 20.85K | Conversion of Exercise of derivative security |
TESSARI EBEN |
Officer | 23.13K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$6.01B
Enterprise value$5.50B
Revenue (TTM)$840.85M
Gross profit$458.30M
EBITDA$102.04M
Net income$80.66M
EPS (TTM)$1.00
Free cash flow$126.14M
Total cash$525.93M
Total debt$8.90M
Book value / share$8.39
Shares outstanding48.29M
Float39.86M
Short % of float9.70%
Dividend yield0.00%
Beta (5Y)0.04
Valuation & profitability ratios
Trailing P/E77.09
Forward P/E47.66
PEG ratio—
Price / sales—
Price / book9.19
EV / revenue6.54
EV / EBITDA53.88
Gross margin54.50%
Operating margin11.16%
Profit margin9.59%
Return on equity14.04%
Return on assets8.05%
Debt / equity1.36
Current ratio3.90
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $677.56M | $423.24M | $270.26M | $220.18M | — | +60.1% |
| Operating revenue | $677.56M | $423.24M | $270.26M | $220.18M | — | +60.1% |
| Cost of revenue | $307.22M | $60.91M | $33.41M | $22.89M | — | +404.4% |
| Gross profit | $370.35M | $362.33M | $236.85M | $197.28M | — | +2.2% |
| Research & development | $96.85M | $111.62M | $76.10M | $65.49M | — | -13.2% |
| Selling, general & admin | $196.27M | $168.01M | $129.43M | $97.95M | — | +16.8% |
| Total operating expense | $293.13M | $407.94M | $262.05M | $187.51M | — | -28.1% |
| Operating income | $77.22M | -$45.62M | -$25.20M | $9.77M | — | +269.3% |
| Net interest income | — | — | — | $1.25M | $97.00K | — |
| Pre-tax income | $88.87M | -$36.15M | -$16.65M | $11.03M | — | +345.8% |
| Tax provision | $29.86M | $7.04M | -$30.74M | -$172.34M | — | +324.1% |
| Net income | $59.01M | -$43.19M | $14.08M | $183.36M | — | +236.6% |
| Net income to common | $59.01M | -$43.19M | $14.08M | $183.36M | — | +236.6% |
| Basic EPS | 0.80 | -0.60 | 0.20 | 2.64 | — | +233.3% |
| Diluted EPS | 0.75 | -0.60 | 0.20 | 2.60 | — | +225.0% |
| EBIT | $77.22M | -$45.62M | -$25.20M | $9.77M | — | +269.3% |
| EBITDA | $78.78M | -$43.92M | -$22.86M | $12.18M | — | +279.4% |
| Basic shares | 74.20M | 71.42M | 70.06M | 69.38M | — | +3.9% |
| Diluted shares | 78.98M | 71.42M | 71.92M | 70.42M | — | +10.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $165.60M | $183.58M | $107.95M | $122.72M | -9.8% |
| Cash & short-term investments | $414.07M | $243.63M | $206.37M | $190.61M | +70.0% |
| Accounts receivable | $15.59M | $41.72M | $21.27M | $12.66M | -62.6% |
| Inventory | $54.90M | $26.36M | $31.12M | $21.60M | +108.2% |
| Total current assets | $527.18M | $331.80M | $276.30M | $243.06M | +58.9% |
| Property, plant & equipment | $11.75M | $11.04M | $12.66M | $7.04M | +6.5% |
| Goodwill & intangibles | $15.25M | $16.25M | $17.25M | $18.25M | -6.2% |
| Total assets | $763.63M | $580.55M | $526.32M | $459.67M | +31.5% |
| Total current liabilities | $139.18M | $100.62M | $63.67M | $47.07M | +38.3% |
| Total debt | $9.50M | $9.86M | $12.26M | $5.92M | -3.6% |
| Total liabilities | $196.03M | $142.12M | $87.48M | $63.52M | +37.9% |
| Retained earnings | -$462.14M | -$521.14M | -$477.95M | -$492.03M | +11.3% |
| Shareholder equity | $567.61M | $438.44M | $438.84M | $396.15M | +29.5% |
| Working capital | $387.99M | $231.18M | $212.63M | $195.99M | +67.8% |
| Net tangible assets | $552.36M | $422.19M | $421.59M | $377.90M | +30.8% |
| Shares issued | 76.29M | 72.52M | 70.46M | 69.70M | +5.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $59.01M | -$43.19M | $14.08M | $183.36M | +236.6% |
| Depreciation & amortisation | $1.55M | $1.70M | $2.34M | $2.40M | -8.3% |
| Stock-based compensation | $37.00M | $30.69M | $27.15M | $25.12M | +20.6% |
| Change in working capital | $24.79M | $24.81M | $1.35M | -$22.57M | -0.1% |
| Operating cash flow | $137.99M | $25.69M | $13.30M | $5.81M | +437.1% |
| Capital expenditure | -$1.57M | -$277.00K | -$130.00K | -$105.00K | -466.1% |
| Investing cash flow | -$188.99M | $37.67M | -$29.56M | -$8.08M | -601.7% |
| Share buybacks | -$7.73M | -$4.98M | -$2.21M | -$901.00K | -55.1% |
| Financing cash flow | $33.02M | $12.27M | $1.50M | $2.52M | +169.2% |
| Free cash flow | $136.42M | $25.41M | $13.17M | $5.70M | +436.8% |
| End cash position | $165.60M | $183.58M | $107.95M | $122.72M | -9.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $243.60M | $214.27M | $202.13M | $180.85M | $156.80M | +13.7% |
| Operating revenue | $243.60M | $214.27M | $202.13M | $180.85M | $156.80M | +13.7% |
| Cost of revenue | $111.64M | $96.37M | $90.97M | $83.56M | $71.02M | +15.8% |
| Gross profit | $131.96M | $117.89M | $111.15M | $97.29M | $85.78M | +11.9% |
| Research & development | $40.90M | $27.48M | $34.61M | $24.17M | $18.75M | +48.9% |
| Selling, general & admin | $63.87M | $61.15M | $56.77M | $49.10M | $46.86M | +4.4% |
| Total operating expense | $104.77M | $88.63M | $91.38M | $73.27M | $65.62M | +18.2% |
| Operating income | $27.19M | $29.27M | $19.77M | $24.02M | $20.16M | -7.1% |
| Pre-tax income | $31.14M | $32.68M | $23.27M | $27.16M | $22.88M | -4.7% |
| Tax provision | $5.71M | $10.09M | $9.07M | $8.72M | $5.04M | -43.4% |
| Net income | $25.43M | $22.59M | $14.20M | $18.43M | $17.83M | +12.6% |
| Net income to common | $25.43M | $22.59M | $14.20M | $18.43M | $17.83M | +12.6% |
| Basic EPS | 0.33 | 0.30 | 0.19 | 0.25 | 0.24 | +10.0% |
| Diluted EPS | 0.30 | 0.27 | 0.17 | 0.23 | 0.23 | +11.1% |
| EBIT | $27.19M | $29.27M | $19.77M | $24.02M | $20.16M | -7.1% |
| EBITDA | $27.67M | $29.73M | $20.23M | $24.41M | $20.52M | -7.0% |
| Basic shares | 77.58M | 76.52M | 75.97M | 74.71M | 73.44M | +1.4% |
| Diluted shares | 83.40M | 82.41M | 81.57M | 80.04M | 77.94M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $175.68M | $189.95M | $165.60M | $174.86M | $192.04M | -7.5% |
| Cash & short-term investments | $525.93M | $468.09M | $414.07M | $352.10M | $307.78M | +12.4% |
| Accounts receivable | $23.49M | $23.22M | $15.59M | $51.74M | $31.91M | +1.1% |
| Inventory | $70.93M | $73.14M | $54.90M | $41.40M | $48.18M | -3.0% |
| Total current assets | $668.63M | $594.17M | $527.18M | $475.53M | $420.31M | +12.5% |
| Property, plant & equipment | $10.93M | $11.32M | $11.75M | $11.73M | $11.38M | -3.5% |
| Goodwill & intangibles | $14.75M | $15.00M | $15.25M | $15.50M | $15.75M | -1.7% |
| Total assets | $896.11M | $825.28M | $763.63M | $712.33M | $661.15M | +8.6% |
| Total current liabilities | $171.25M | $156.61M | $139.18M | $123.59M | $117.83M | +9.3% |
| Total debt | $8.90M | $9.03M | $9.50M | $9.72M | $9.77M | -1.4% |
| Total liabilities | $241.96M | $219.59M | $196.03M | $176.95M | $166.14M | +10.2% |
| Retained earnings | -$414.11M | -$439.55M | -$462.14M | -$476.34M | -$494.77M | +5.8% |
| Shareholder equity | $654.15M | $605.69M | $567.61M | $535.38M | $495.01M | +8.0% |
| Working capital | $497.39M | $437.56M | $387.99M | $351.94M | $302.48M | +13.7% |
| Net tangible assets | $639.40M | $590.69M | $552.36M | $519.88M | $479.26M | +8.2% |
| Shares issued | 77.98M | 76.69M | 76.29M | 75.42M | 74.03M | +1.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $25.43M | $22.59M | $14.20M | $18.43M | $17.83M | +12.6% |
| Depreciation & amortisation | $472.00K | $468.00K | $467.00K | $384.00K | $358.00K | +0.9% |
| Stock-based compensation | $11.64M | $10.06M | $10.23M | $10.14M | $8.88M | +15.7% |
| Change in working capital | $5.87M | $10.32M | $25.88M | -$1.02M | -$1.67M | -43.1% |
| Operating cash flow | $47.20M | $50.20M | $53.89M | $33.68M | $28.09M | -6.0% |
| Capital expenditure | -$663.00K | -$161.00K | -$633.00K | -$671.00K | -$165.00K | -311.8% |
| Investing cash flow | -$73.58M | -$31.92M | -$70.81M | -$62.76M | -$3.88M | -130.5% |
| Share buybacks | -$5.47M | -$316.00K | -$918.00K | -$4.35M | -$2.05M | -1,630.4% |
| Financing cash flow | $12.11M | $6.07M | $7.66M | $11.90M | $10.70M | +99.4% |
| Free cash flow | $46.53M | $50.04M | $53.26M | $33.01M | $27.93M | -7.0% |
| End cash position | $175.68M | $189.95M | $165.60M | $174.86M | $192.04M | -7.5% |
Options analytics
Put / call volume
0.43
Call-heavy session
Put / call open interest
0.16
Positioning, not flow
Max pain
65.00
-15.7% from spot
ATM implied vol
66.8%
Nearest strike to spot
Skew (10% OTM)
+17.1%
Puts bid over calls
Call volume
47
Contracts, this expiry
Put volume
20
Contracts, this expiry
Heaviest call OI
65.00
378 contracts
Heaviest put OI
75.00
66 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.29 | 0.30 | +5.3% |
| Mar 2026 | 0.16 | 0.27 | +68.8% |
| Dec 2025 | 0.40 | 0.17 | -57.3% |
| Sep 2025 | 0.37 | 0.23 | -37.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.32 | 4 | $259.60M | +43.5% |
| Next quarter | 0.29 | 4 | $276.14M | +36.6% |
| Current year | 1.16 | 4 | $993.71M | +46.7% |
| Next year | 1.62 | 4 | $1.22B | +22.9% |
Analyst targets & ownership
Mean target$98.00
High target$108.00
Low target$87.00
Implied upside27.77%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders3.51%
Held by institutions101.02%
Institutions holding384
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
75.73
+1.27% from price
SMA 20
76.53
+0.73% from price
SMA 50
77.54
-0.58% from price
SMA 100
67.26
+14.03% from price
SMA 200
56.57
+36.28% from price
EMA 12
76.25
+0.59% from price
EMA 26
76.44
+0.35% from price
EMA 50
74.59
+2.82% from price
RSI (14)
52.6
Neutral
MACD (12,26,9)
-0.18
Hist -0.11
ATR (14)
2.43
3.16% of price
Realised vol 30D
25.4%
Annualised
Bollinger upper
79.03
20, 2σ
Bollinger lower
74.04
20, 2σ
50 / 200 cross
Golden
77.54 vs 56.57
Trend bias
Above 200
+36.28%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.23
Less volatile than market
Correlation to SPY
0.06
Largely independent
Realised vol 30D
25.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-21.1%
Peak to trough
Max drawdown 5Y
-49.8%
Peak to trough
ATR 14
2.43
3.16% of price
Beta (reported)
0.04
5Y monthly, from filing
Short interest
Shares short
3.88M
Prior 4.28M
Change vs prior
-9.5%
Shorts covering
% of float
9.70%
Normal
% of shares out
4.97%
Against total outstanding
Days to cover
7.9
Crowded exit
Float
39.86M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 30, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Jul 29, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 29, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 29, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 29, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 23, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jun 29, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 29, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Apr 29, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Apr 29, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 29, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-26
Corporate Changes & Voting Matters
8-K · 2026-05-01
Periodic Financial Reports
10-Q · 2026-04-28
Proxy Statements
DEFA14A · 2026-04-16
Periodic Financial Reports
10-K · 2026-02-24
Corporate Changes & Voting Matters
8-K · 2026-01-14
Headlines
Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued
Simply Wall St. · 13d ago
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Zacks · 19d ago
Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
Investor's Business Daily · 26d ago
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
GlobeNewswire · 32d ago
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Investor's Business Daily · 43d ago
Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
Investor's Business Daily · 46d ago
Three Biotech Stocks Stick Out With Their Stellar Charts
Investor's Business Daily · 46d ago
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
MarketBeat · 53d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.